Efficient lowering of triglyceride levels in mice by human apoAV protein variants associated with hypertriglyceridemia

Biochemical and Biophysical Research Communications

Volumn 379, Issue 2, 2009, Pages 542-546

  Vaessen, Stefan F C ^a   Sierts, Jeroen A ^a   Kuivenhoven, Jan Albert ^a   Schaap, Frank G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adenovirus; Apolipoprotein; LPL; Mutation analysis; SNP

Indexed keywords

APOLIPOPROTEIN; FATTY ACID; GLYCEROL; LIPOPROTEIN LIPASE; PROTEIN APOAV; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; HYPERTRIGLYCERIDEMIA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN VARIANT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEINS A; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MICE; MICE, INBRED C57BL; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

ADENOVIRIDAE; MUS;

EID: 58149487848     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.115     Document Type: Article

References (39)

1. Nordestgaard B.G., Benn M., Schnohr P., and Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (2007) 299-308
2. Schaap F.G., Rensen P.C., Voshol P.J., Vrins C., Van der Vliet H.N., Chamuleau R.A., Havekes L.M., Groen A.K., and van Dijk K.W. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279 (2004) 27941-27947
3. Merkel M., Loeffler B., Kluger M., Fabig N., Geppert G., Pennacchio L.A., Laatsch A., and Heeren J. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan bound lipoprotein lipase. J. Biol. Chem. 280 (2005) 21553-21560
4. Lookene A., Beckstead J.A., Nilsson S., Olivecrona G., and Ryan R.O. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J. Biol. Chem. 280 (2005) 25383-25387
5. Nilsson S.K., Lookene A., Beckstead J.A., Gliemann J., Ryan R.O., and Olivecrona G. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry 46 (2007) 3896-3904
6. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R., Fruchart J.C., Krauss R.M., and Rubin E.M. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
7. Marcais C., Verges B., Charriere S., Pruneta V., Merlin M., Billon S., Perrot L., Drai J., Sassolas A., Pennacchio L.A., Fruchart-Najib J., Fruchart J.C., Durlach V., and Moulin P. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J. Clin. Invest. 115 (2005) 2862-2869
8. Priore Oliva C., Pisciotta L., Li V.G., Sambataro M.P., Cantafora A., Bellocchio A., Catapano A., Tarugi P., Bertolini S., and Calandra S. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 411-417
9. Priore Oliva C., Carubbi F., Schaap F.G., Bertolini S., and Calandra S. Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene. J. Intern. Med. 263 (2008) 450-458
10. Kao J.T., Wen H.C., Chien K.L., Hsu H.C., and Lin S.W. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum. Mol. Genet. 12 (2003) 2533-2539
11. Mar R., Pajukanta P., Allayee H., Groenendijk M., Dallinga-Thie G., Krauss R.M., Sinsheimer J.S., Cantor R.M., de Bruin T.W., and Lusis A.J. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ. Res. 94 (2004) 993-999
12. Lai C.Q., Demissie S., Cupples L.A., Zhu Y., Adiconis X., Parnell L.D., Corella D., and Ordovas J.M. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J. Lipid Res. 45 (2004) 2096-2105
13. Tang Y., Sun P., Guo D., Ferro A., Ji Y., Chen Q., and Fan L. A genetic variant c.553G>T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. Atherosclerosis 85 (2005) 433-437
14. Pennacchio L.A., Olivier M., Hubacek J.A., Krauss R.M., Rubin E.M., and Cohen J.C. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet. 11 (2002) 3031-3038
15. Prieur X., Coste H., and Rodriguez J.C. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J. Biol. Chem. 278 (2003) 25468-25480
16. Prieur X., Schaap F.G., Coste H., and Rodriguez J.C. Hepatocyte nuclear factor-4alpha regulates the human apolipoprotein AV gene: identification of a novel response element and involvement in the control by peroxisome proliferator-activated receptor-gamma coactivator-1alpha, AMP-activated protein kinase, and mitogen-activated protein kinase pathway. Mol. Endocrinol. 19 (2005) 3107-3125
17. Ruge T., Svensson M., Eriksson J.W., and Olivecrona G. Tissue-specific regulation of lipoprotein lipase in humans: effects of fasting. Eur. J. Clin. Invest. 35 (2005) 194-200
18. Talmud P.J., Palmen J., Putt W., Lins L., and Humphries S.E. Determination of the functionality of common APOA5 polymorphisms. J. Biol. Chem. 280 (2005) 28215-28220
19. Olivier M., Wang X., Cole R., Gau B., Kim J., Rubin E.M., and Pennacchio L.A. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 83 (2004) 912-923
20. Ahituv N., Akiyama J., Chapman-Helleboid A., Fruchart J., and Pennacchio L.A. In vivo characterization of human APOA5 haplotypes. Genomics 90 (2007) 674-679
21. Talmud P.J., Cooper J.A., Hattori H., Miller I.P., Miller G.J., and Humphries S.E. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia 49 (2006) 2337-2340
22. Vaessen S.F., Schaap F.G., Kuivenhoven J.A., Groen A.K., Hutten B.A., Boekholdt S.M., Hattori H., Sandhu M.S., Bingham S.A., Luben R., Palmen J.A., Wareham N.J., Humphries S.E., Kastelein J.J., Talmud P.J., and Khaw K.T. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J. Lipid Res. 47 (2006) 2064-2070
23. Dorfmeister B., Zeng W.W., Dichlberger A., Nilsson S.K., Schaap F.G., Hubacek J.A., Merkel M., Cooper J.A., Lookene A., Putt W., Whittall R., Lee P.J., Lins L., Delsaux N., Nierman M., Kuivenhoven J.A., Kastelein J.J., Vrablik M., Olivecrona G., Schneider W.J., Heeren J., Humphries S.E., and Talmud P.J. Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1866-1871
24. Mittereder N., March K.L., and Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70 (1996) 7498-7509
25. Levels J.H., Abraham P.R., vanden E.A., and vanDeventer S.J. Distribution and kinetics of lipoprotein-bound endotoxin. Infect. Immun. 69 (2001) 2821-2828
26. Liu G., Ashbourne Excoffon K.J., Wilson J.E., McManus B.M., Rogers Q.R., Miao L., Kastelein J.J., Lewis M.E., and Hayden M.R. Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. Hum. Gene Ther. 11 (2000) 21-32
27. Dallinga-Thie G.M., Zonneveld-de Boer A.J., van Vark-van der Zee L.C., van H.R., van G.T., Jansen H., De C.R., and van T.A. Appraisal of hepatic lipase and lipoprotein lipase activities in mice. J. Lipid Res. 48 (2007) 2788-2791
28. Talmud P.J. Rare APOA5 mutations-clinical consequences, metabolic and functional effects: an ENID review. Atherosclerosis 194 (2007) 287-292
29. Sunyaev S., Ramensky V., Koch I., Lathe III W., Kondrashov A.S., and Bork P. Prediction of deleterious human alleles. Hum. Mol. Genet. 10 (2001) 591-597
30. Ng P.C., and Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31 (2003) 3812-3814
31. Beckstead J.A., Wong K., Gupta V., Wan C.P., Cook V.R., Weinberg R.B., Weers P.M., and Ryan R.O. The C terminus of apolipoprotein A-V modulates lipid-binding activity. J. Biol. Chem. 282 (2007) 15484-15489
32. Schaap F.G., Nierman M.C., Berbee J.F., Hattori H., Talmud P.J., Vaessen S.F., Rensen P.C., Chamuleau R.A., Kuivenhoven J.A., and Groen A.K. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J. Lipid Res. 47 (2006) 2333-2339
33. Dallinga-Thie G.M., van Tol A., Hattori H., van Vark-van der Zee L.C., Jansen H., and Sijbrands E.J. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia 49 (2006) 1505-1511
34. van der Vliet H.N., Schaap F.G., Levels J.H., Ottenhoff R., Looije N., Wesseling J.G., Groen A.K., and Chamuleau R.A. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem. Biophys. Res. Commun. 295 (2002) 1156-1159
35. Liu Q., and Muruve D.A. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 10 (2003) 935-940
36. Grosskopf I., Baroukh N., Lee S.J., Kamari Y., Harats D., Rubin E.M., Pennacchio L.A., and Cooper A.D. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2573-2579
37. Turcotte L.P., Petry C., Kiens B., and Richter E.A. Contraction-induced increase in Vmax of palmitate uptake and oxidation in perfused skeletal muscle. J. Appl. Physiol 84 (1998) 1788-1794
38. Jensen M.D., Chandramouli V., Schumann W.C., Ekberg K., Previs S.F., Gupta S., and Landau B.R. Sources of blood glycerol during fasting. Am. J. Physiol. Endocrinol. Metab. 281 (2001) E998-E1004
39. Hubacek J.A., Skodova Z., Adamkova V., Lanska V., and Poledne R. Sex-specific effect of APOAV variant (Val153>Met) on plasma levels of high-density lipoprotein cholesterol. Metabolism 54 (2005) 1632-1635